Table 3 Univariate analyses for progression-free survival (PFS)

Age

    < 65y

29 (64)

11

1

    ≥ 65y

16 (36)

6

1.4 (0.7-3)

0.31

Gender

    Male

31 (69)

7

1

    Female

14 (31)

7

1.1 (0.5–2.5)

0.75

ECOG

    0–1

34 (76)

7

1

    ≥ 2

11 (24)

6

1.1 (0.4-2)

0.95

IMDC Risk Group

    Favorable

7 (16)

4

1

    Intermediate

36 (80)

7

0.5 (0.3–5.6)

0.20

    Poor

2 (4)

1

0.7 (0.2–13)

0.70

Tumor Histology

    Non-clear Cell

6 (13)

7

1

    Clear Cell

39 (87)

7

1 (0.3–3.4)

0.90

BMI kg/ m ²

    < 25

22 (49)

7

1

    25-29.9

14 (31)

4

1 (0.5–2.6 )

0.70

    ≥ 30

9 (20)

5

0.9 (0.3–2.5 )

0.90

Basal Splenic Volume

    < median 280 ml

23 (51)

5

1

    ≥ median 280 ml

22 (49)

7

0.9 (0.4–1.8)

0.72

Splenic Volume (%)

    Not increased

23 (51)

17

1.0

    İncreased

22 (49)

5

2.1 (1–4)

0.04

NLR

    <median 3.40

19 (42)

8

1

    ≥median 3.40

26 (58)

5

1.7 (0.8–3.5)

0.19

PLR

    <median 206

20 (44)

11

1

    ≥median 206

25 (56)

5

1.6 (0.8–3.5)

0.19